Regulus reducing headcount by 60%

Regulus Therapeutics Inc. (NASDAQ:RGLS) reduced its headcount by an additional 60% and paused recruitment efforts for its RG-012 clinical program in Alport syndrome

Read the full 233 word article

User Sign In